Navigation Links
Victhom Announces Launch of Enhanced Company Website
Date:1/9/2009

QUEBEC, Jan. 9 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., "Victhom" (TSX: VHB), today announced the unveiling of its updated corporate Website at www.victhom.com. The Website features a new structure that highlights advances in the Company's two operating divisions; Neurobionix, which is developing an implantable neurostimulation device for gait disorders, and Biotronix, which is developing and manufacturing computerized prostheses for above-knee amputees.

Commenting on the new Website, Normand Rivard, Acting President and Chief Financial Officer, stated: "The new layout provides users with more intuitive navigation, enhanced visual content and a comprehensive view of the Company's technologies and products". He went on to say, "This redesigned Website affirms our commitment to provide relevant information and educate all of our stakeholders including patients, medical professionals, investors, and current and future business partners".

The Neurobionix division portion of the Website includes a new "Patient section" that provides information on the impact of cerebral stroke and a particular aspect of gait disorder known as foot drop. This section presents contemporary treatment options for foot drop sufferers as well as the emerging use of neurostimulation devices that provide instantaneous assistance to patients.

A new "Medical Professional section" has been added and designed for use by members of the professional medical community. This section provides medical and technical information on the Company's proprietary implantable assistive device known as Neurostep(R), which is currently in clinical trials and designed to restore mobility to persons suffering from foot drop. Information about the product includes a new animation video demonstrating various aspects of the Neurostep(R) System as well as updates regarding the Company's clinical activities.

The Biotronix division section highlights the Company's biomechatronic technology capabilities and specifically the Power Knee, a motorized battery-powered transfemoral prosthesis for above-knee amputees exclusively distributed by our business partner Ossur hf (www.ossur.com).

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix division focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix division develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market.

FORWARD-LOOKING STATEMENTS

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.


'/>"/>
SOURCE VICTHOM HUMAN BIONICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
2. Victhom to Participate in the OneMedPlace Finance Forum
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  In the pharmaceutical industry the medical affairs ... launch activities including the identification and engagement of key ... especially high in the oncology therapeutic area where most ... the Role of Medical Affairs in Oncology Launch Excellence ... therapies find better ways to utilize medical affairs to ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... Francisco, CA (PRWEB) , ... February 04, 2016 ... ... of enterprise talent development and compliance training, today announced an interactive FDA ... Morf Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course on ...
(Date:2/4/2016)... 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... Edward Lanphier , Sangamo,s president and chief executive ... Sangamo,s ZFP Therapeutic ® development programs and an ... ET on Thursday, February 11, 2016, at the Leerink ... conference is being held in New York ...
Breaking Biology Technology:
(Date:1/25/2016)... --  Unisys Corporation (NYSE: UIS ) today announced the ... Airport, New York City , to help ... enter the United States using passports that ... testing of the system at Dulles last year. The system ... January 2016. --> pilot testing of the system ...
(Date:1/20/2016)... , Jan. 20, 2016 A market ... to directly benefit from the explosion in genomics knowledge. ... Howe Sound Research. A range of dynamic trends are ... - personalized medicine - pharmacogenomics - pathogen evolution ... with large markets - greater understanding of the role ...
(Date:1/13/2016)... --> --> ... report titled - Biometric Sensors Market - Global Industry Analysis, ... to the report, the global biometric sensors market was valued at ... US$1,625.8 mn by 2023, expanding at a CAGR of ... the biometric sensors market is expected to reach 1,799.6 ...
Breaking Biology News(10 mins):